John Allan, MD

Highlights

1
British journal of haematology · 2021
JAJohn Allan
PMID: 34865212PMCID: PMC9299890DOIFirst author68 citations
2
Haematologica · 2022
JAJohn Allan RRRichard R Furman
PMID: 34937320PMCID: PMC8968902DOIFirst author36 citations
3
Blood advances · 2025
JAJohn Allan
PMID: 40353821PMCID: PMC12311590DOIFirst author3 citations

Publications

Funding

Completed grants (3)

Co-I
Mechanisms of enhancer regulation in leukemia
National Cancer Institute · 2019–2023 · via New York University Medical Center
R01CA228135-03
PI
Zanubrutinib and Venetoclax as Initial Therapy for CLL with Obinutuzumab Consolidation in Patients with Minimal Residual Disease Positivity.
Conquer Cancer Foundation of the American Society of Clinical Oncology · 2022–2023
ASCO 221054-01
PI
Potential Genetic and Transcriptomic Mechanisms of Resistance to BTK Inhibition in CLL
Celgene Corporation · 2019–2022Contract
SRA 185304-01

Clinical research

Active

7 studies

PI
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
PHASE1; PHASE2 · BeiGene USA · OPEN TO ACCRUAL (as of 2026)
B-cell Malignancy; Relapsed Cancer; Refractory Cancer; B-cell Lymphoma
NCT06634589
PI
I+V-LT: Long-term follow-up of ibrutinib plus venetoclax in patients with treatment-naive CLL/SLL
European Research Initiative on CLL · OPEN TO ACCRUAL (as of 2026)
PI
Minimal residual disease monitoring via circulating tumor DNA for diffuse large B-cell lymphoma
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
PI
Evaluating Once Daily Zanubrutinib use in CLL/SLL
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
PI
Impact of Variable Antigen Expression on Behavior of CLL and Small B-Cell Lymphomas
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
PI
Phase II Study of Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
PHASE2 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2023)
Richter Syndrome; Chronic Lymphocytic Leukemia
NCT04679012
PI
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
PHASE1; PHASE2 · BeiGene USA · OPEN TO ACCRUAL (as of 2022)
B-cell Malignancy; Marginal Zone Lymphoma; Follicular Lymphoma; Non-Hodgkin Lymphoma; Waldenström Macroglobulinemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Richter Transformation
NCT05006716

Completed & closed trials (13)

PI
An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)
PHASE1 · Regeneron Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2026)
Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia
NCT02290951
PI
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
PHASE2 · ECOG-ACRIN Cancer Research Group · IRB STUDY CLOSURE (as of 2026)
Liver Lymphoma; Mantle Cell Lymphoma
NCT04115631
PI
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
PHASE2 · Regeneron Pharmaceuticals, Inc. · CLOSED TO ACCRUAL (as of 2025)
B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT03888105
PI
Zanubrutinib and Venetoclax as Initial Therapy for CLL With Obinutuzumab Consolidation in Patients With Minimal Residual Disease Positivity (BruVenG)
PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
Leukemia, Lymphocytic, Chronic, B-Cell
NCT05650723
PI
Phase II Study of Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
PHASE2 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
Chronic Lymphocytic Leukemia; CLL Progression; CLL/SLL
NCT04149821
PI
A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
PHASE2 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
Waldenstrom Macroglobulinemia; Waldenstrom's Disease; Waldenström; Hypergammaglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia of Lymph Nodes; Waldenstrom's Macroglobulinaemia, Without Mention of Remission; Waldenstrom's Macroglobulinemia Refractory
NCT03679624
PI
Hypertension in Patients Treated with Bruton Tyrosine Kinase Inhibitors for Lymphoid Malignancies: Treatment Efficacy and Cardiovascular Outcomes
Fred Hutchinson Cancer Research Center · CLOSED TO ACCRUAL (as of 2024)
PI
A Phase Ib /II Open-label, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)
PHASE1 · Ascentage Pharma Group Inc · IRB STUDY CLOSURE (as of 2024)
Waldenstrom Macroglobulinemia
NCT04260217
PI
Examining COVID-19 course and outcomes in patients previously diagnosed with chronic lymphocytic leukemia (CLL)
Memorial Sloan Kettering Cancer Center · IRB STUDY CLOSURE (as of 2024)
PI
Secondary Primary Neoplasms in indolent Non-Hodgkin Lymphoma Patients on Novel Oral Agents
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
PI
Real World Experience of Follicular Lymphoma Patients Treated with Lenalidomide: A Multi-Center Retrospective Study.
Swedish Cancer Institute · CLOSED TO ACCRUAL (as of 2022)
PI
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
PHASE3 · Alliance for Clinical Trials in Oncology · IRB STUDY CLOSURE (as of 2022)
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT03737981
PI
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
PHASE1; PHASE2 · Tolero Pharmaceuticals Inc. · IRB STUDY CLOSURE (as of 2020)
Chronic Lymphocytic Leukemia; CLL; SLL; Small Lymphocytic Lymphoma
NCT03572634

External relationships

Professional Services

Merck & Co., Inc.

Other

AbbVie Inc. · Adaptive Biotechnologies · Aptitude Health · AstraZeneca, PLC · BeiGene USA · Clinical Care Options, LLC · Curio Science LLC · Dava Oncology · Johnson & Johnson · Lilly USA, LLC · MJH Life Sciences · MLI-Peerview · NeoGenomics Laboratories, Inc. · Pfizer, Inc. · Plexus Communications · Research to Practice, Inc.